Stephen A. Tullman, Director at Aclaris Therapeutics, Inc. (ACRS), bought 26,700 shares at $16.54 ($442K) on 2018-04-06, disclosed to the SEC on 2018-04-09.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| ACRS | BUY | 2018-08-17 | $200K | — | Filing → |